Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients

Cytran200 enrolled

Overview

The purpose of this study is to see if it is safe and effective to use IM862 to treat Kaposi's sarcoma (KS) in AIDS patients.

Patients are stratified by CD4 count, viral load, and prior systemic chemotherapy. Patients are randomized equally to receive either IM862 or placebo given intranasally every other day. Patients are seen every 4 weeks for 6 months or until disease progression to evaluate toxicity and efficacy. Quality of life is assessed before treatment, then every month for 6 months. At the end of the 6-month study evaluation period, patients with PR/CR (responders) remain on study and continue blinded treatment for an additional 6 months. For patients with stable disease (non-responders), the treatment assignment is unblinded and off-study IM862 compassionate use is offered for 6 months, regardless of treatment group. For patients with documented progressive disease (treatment failure), the treatment assignment is unblinded and off-study IM862 is offered for 6 months to any patient in the placebo group. For treatment failures in the IM862 group, IM862 is stopped and the patient is allowed other therapy options.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

200

Conditions

Sarcoma, Kaposi HIV Infections

Interventions

IM862DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria Patients may be eligible for this study if they: * Are HIV-positive. * Have AIDS-related Kaposi's sarcoma. * Have at least 5 skin or mouth sores that do not require chemotherapy. * Have been taking anti-HIV drugs for at least 8 weeks before study entry with no changes in the regimen. * Are at least 18 years old. * Agree to practice effective methods of birth control. Exclusion Criteria Patients will not be eligible for this study if they: * Have an AIDS-related opportunistic infection (except for genital herpes) within 2 weeks of study entry. * Have had another type of cancer within the past 2 years (except for certain types of skin cancer, cervical cancer, or anal cancer). * Have a severe chest cold. * Have certain other serious medical conditions. * Have received certain medications, including chemotherapy, within the past 4 weeks. * Abuse alcohol or drugs. * Are pregnant or breast-feeding.

Locations (42)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

AIDS Healthcare Foundation